Bortezomib is the first-line drug in the treatment of multiple myeloma (MM) and its resistance is the main obstacle to cure MM. MicroRNA-361-5p (MiRNA-361-5p) in bone marrow mesenchymal stem cells (BMSCs) might participate in the bortezomib resistance via paracrine pathway. The study was to characterize the role and molecular mechanism of miR-361-5p in bortezomib resistance in MM.
Methods
The exosomes of BMSCs were obtained and characterized by transmission electron microscopy and nanoparticle tracking analysis. The MM cell U266 was treated with bortezomib, bortezomib and BMSC exosomes, bortezomib and BMSC exosomes transfected with miR-361-5p inhibitor. The cell viability was measured by cell counting kit. Protein expression of PDPK1, PI3K, p-PI3K, mTOR, p-mTOR, AKT, and Pan-AKT was detected by western blot. The apoptosis level of bortezomib resistant cell lines was detected by flow cytometry.
Results
Low expression of miR-361-5p promoted the survival of U266 cells and inhibited cell apoptosis, reversing the inhibitory effect of bortezomib on U266 cells. PDPK1 may be a downstream target of miR-361-5p. Low expression of BMSCs-derived exosomal miR-361-5p may reverse the effect of bortezomib on U266 cells by regulating the PDPK1/PI3K/AKT/mTOR axis.
Conclusion
Low expression of BMSCs-derived exosomal miR-361-5p may overcome bortezomib resistance in MM by regulating PDPK1/PI3K/AKT/mTOR axis.
AbdiJChenGChangH. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget2013; 4: 2186–2207.
2.
Chang-ChanDYRíos-TamayoRRodríguez BarrancoM, et al.Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clin Transl Oncol2021; 23: 1429–1439.
3.
HeJHeDHanX, et al.Bortezomib-based regimens for newly diagnosed multiple myeloma in China: a report of 12-year real-world data. Front Pharmacol2020; 11: 561601.
4.
KozalakGBütünİToyranE,et al.Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies. Pharmaceuticals (Basel)2023; 16: 111.
5.
LeeSWYeonS-KKimGW, et al.HDAC6-Selective Inhibitor overcomes bortezomib resistance in multiple myeloma. Int J Mol Sci2021; 22: 1341.
TanCRCAbdul-MajeedSCaelB,et al.Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin Pharmacokinet2019; 58: 157–168.
8.
DouQP. Resistance to proteasome inhibitors in cancer. Molecular mechanisms and strategies to overcome resistance. Cham, Switzerland: Springer Cham, 2014.
9.
MaisoPHuynhDMoschettaM, et al.Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res2015; 75: 2071–2082.
10.
LemaireMDeleuSDe BruyneE, et al.The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res2011; 110: 19–42.
11.
MahindraAHideshimaTAndersonKC. Multiple myeloma: biology of the disease. Blood Rev2010; 24: S5–S11.
12.
ChenTMoscvinMBianchiG. Exosomes in the pathogenesis and treatment of multiple myeloma in the context of the bone marrow microenvironment. Front Oncol2020; 10: 608815.
13.
WangJHendrixAHernotS, et al.Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood2014; 124: 555–566.
14.
SolimanAMLinTSMahakkanukrauhP,et al.Role of microRNAs in diagnosis, prognosis and management of multiple myeloma. Int J Mol Sci2020; 21: 7539.
15.
ChenWTLuoYChenXM,et al.Role of exosome-derived miRNAs in diabetic wound angiogenesis. Mol Cell Biochem2024; 479: 2565–2580.
16.
GondaliyaPSayyedAABhatP, et al.Mesenchymal stem cell-derived exosomes loaded with miR-155 inhibitor ameliorate diabetic wound healing. Mol Pharm2022; 19: 1294–1308.
17.
SongXJZhangLLiQ, et al.hUCB-MSC derived exosomal miR-124 promotes rat liver regeneration after partial hepatectomy via downregulating Foxg1. Life Sci2021; 265: 118821.
18.
XuJChenPYuC, et al.Hypoxic bone marrow mesenchymal stromal cells-derived exosomal miR-182-5p promotes liver regeneration via FOXO1-mediated macrophage polarization. FASEB J2022; 36: e22553.
19.
HanFWangCChengP, et al.Bone marrow mesenchymal stem cells derived exosomal miRNAs can modulate diabetic bone-fat imbalance. Front Endocrinol (Lausanne)2023; 14: 1149168.
20.
ZhangZYLiYCGengCY, et al.Potential relationship between clinical significance and serum exosomal miRNAs in patients with multiple myeloma. Biomed Res Int2019; 2019: 1575468.
21.
LingJHeP. miR-361-5p regulates ovarian cancer cell proliferation and apoptosis by targeting TRAF3. Exp Ther Med2021; 21: 199.
22.
LiuBLuBWangX, et al.MiR-361-5p inhibits cell proliferation and induces cell apoptosis in retinoblastoma by negatively regulating CLDN8. Childs Nerv Syst2019; 35: 1303–1311.
23.
MaFZhangLMaL, et al.MiR-361-5p inhibits glycolytic metabolism, proliferation and invasion of breast cancer by targeting FGFR1 and MMP-1. J Exp Clin Cancer Res2017; 36: 158.
24.
QianBZhangDTaoR, et al.MiR-361-5p exerts tumor-suppressing functions in gastric carcinoma by targeting syndecan-binding protein. Anticancer Drugs2020; 31: 131–140.
25.
RenQXiaoXLengX, et al.MicroRNA-361-5p induces hepatocellular carcinoma cell apoptosis and enhances drug sensitivity by targeting MAP3K9. Exp Ther Med2021; 21: 574.
26.
FanZWuZYangB. The effect of miR-361-3p targeting TRAF6 on apoptosis of multiple myeloma cells. J Microbiol Biotechnol2021; 31: 197–206.
27.
DuJLiuSHeJ, et al.MicroRNA-451 regulates stemness of side population cells via PI3K/akt/mTOR signaling pathway in multiple myeloma. Oncotarget2015; 6: 14993–15007.
28.
LiuSZhangYHuangC,et al.miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway. J Cell Biochem2020; 121: 1475–1490.
29.
ShuyanLYunZShengyunL. Exploration of mechanism of bortezomib on side population cell from multiple myeloma based on PI3K/AKT/mTOR. Chin J Gen Pract2020; 18: 365.
30.
HoMChenTLiuJ, et al.Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. Leukemia2020; 34: 196–209.
31.
RibattiDNicoBVaccaA. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene2006; 25: 4257–4266.
32.
BadnjevićAPokvićLGSmajlhodžić-DeljoM, et al.Application of artificial intelligence for the classification of the clinical outcome and therapy in patients with viral infections: the case of COVID-19. Technol Health Care2024; 32: 1859–1870.
33.
HafizovićLČauševićADeumićA, et al.The use of artificial intelligence in diagnostic medical imaging: systematic literature review. In: 2021 IEEE 21st International Conference on Bioinformatics and Bioengineering (BIBE), Kragujevac, Serbia, 2021, pp. 1–6.
34.
VeljovićEŠpirtović-HalilovićSMuratovićS, et al.Artificial neural network and docking study in design and synthesis of xanthenes as antimicrobial agents. In: BadnjevicA (ed.) CMBEBIH 2017. IFMBE Proceedings, vol. 62. Singapore: Springer, 2017, pp. 617–626.
35.
SpahićLSredovićUKurpejovićZ, et al.Machine learning for improved medical device management: a focus on infant incubators. Technol Health Care2025; 33: 2034–2040.
36.
MedjedovicEStanojevicMJonuzovic-ProsicS, et al.Artificial intelligence as a new answer to old challenges in maternal-fetal medicine and obstetrics. Technol Health Care2024; 32: 1273–1287.
37.
AllegraADi GioacchinoMTonacciA,et al.Multiple myeloma cell-derived exosomes: implications on tumorigenesis, diagnosis, prognosis and therapeutic strategies. Cells2021; 10: 2865.
38.
ZhangYYangPWangXF. Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol2014; 24: 153–160.
39.
DuLBorkowskiRZhaoZ, et al.A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. RNA Biol2013; 10: 1700–1713.
40.
WuHWangQZhongH, et al.Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next–generation sequencing. Oncol Rep2020; 43: 240–250.
41.
MaYBaoCKongR, et al.MicroRNA–361–5p suppresses cancer progression by targeting signal transducer and activator of transcription 6 in non–small cell lung cancer. Mol Med Rep2015; 12: 7367–7373.
42.
ChenYPWangJZhaoK, et al.The plasma miR-125a, miR-361 and miR-133a are promising novel biomarkers for late-onset hypogonadism. Sci Rep2016; 6: 23531.
43.
MaMZhangJGaoX, et al.miR-361-5p mediates SMAD4 to promote porcine Granulosa cell apoptosis through VEGFA. Biomolecules2020; 10: 1281.
44.
LuYWangYXuH,et al.Profilin 1 induces drug resistance through Beclin1 complex-mediated autophagy in multiple myeloma. Cancer Sci2018; 109: 2706–2716.
45.
XieHGuYWangW, et al.Silencing of SENP2 in multiple myeloma induces bortezomib resistance by activating NF-κB through the modulation of IκBα sumoylation. Sci Rep2020; 10: 766.
46.
HuynhMPakCMarkovinaS, et al.Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. J Biol Chem2018; 293: 2452–2465.
47.
YaoYSunYShiM, et al.Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells. Oncotarget2016; 7: 73497–73508.
48.
FangJRhyasenGBolanosL, et al.Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood2012; 120: 858–867.
49.
ZhouJYunEJChenW, et al.Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs. Cell Death Dis2017; 8: e2701.
50.
YangRWangMZhangG, et al.POU2F2 Regulates glycolytic reprogramming and glioblastoma progression via PDPK1-dependent activation of PI3K/AKT/mTOR pathway. Cell Death Dis2021; 12: 433.
51.
ZhangYYangF. Analyzing the disease module associated with osteosarcoma via a network- and pathway-based approach. Exp Ther Med2018; 16: 2584–2592.
52.
JensenHABunaciuRPVarnerJD,et al.GW5074 And PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation. Cell Signal2015; 27: 1666–1675.
53.
MoreauxJLegouffeEJourdanE, et al.BAFF And APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood2004; 103: 3148–3157.
54.
TianLZhaoZXieL,et al.MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget2018; 9: 4886–4896.
55.
ChinenYKurodaJShimuraY, et al.Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma. Cancer Res2014; 74: 7418–7429.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
